Plaintiffs firm Hagens Berman Sobol Shapiro said there was no evidence to suggest its deal to dismiss 28 thalidomide cases against GSK in exchange for the drug company’s agreement not to seek sanctions against the firm was in conflict with its clients’ interests.
The firm further argued that the court and the special master in the cases have no authority to question the accord reached between the plaintiffs and GlaxoSmithKline.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
